Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Panel split as insurers and regulators back expanded reporting on patient assistance; pharma warns of privacy, trade-secret risks
Summary
Supporters including state regulators, insurers and labor groups told the committee SB 1528 A’s expanded reporting of manufacturer patient-assistance programs would improve transparency; industry groups including PhRMA and BIO opposed it, citing trade-secret and privacy concerns.
The House Rules Committee heard competing testimony on Senate Bill 1528 A, which would expand reporting requirements for drug manufacturers’ patient assistance programs to the Department of Consumer and Business Services.
Supporters—including DCBS staff and the Prescription Drug Affordability Board—said current reporting misses important programs and that the change would give policymakers and consumers better data on how assistance programs…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
